Skip to main content

Dosing and Administration

Important Safety Information

WARNINGS AND PRECAUTIONS

  • Radiation Exposure: Treatment with LUTATHERA contributes to a patient’s overall long-term cumulative radiation exposure and is associated with an increased risk for cancer...

Indication

LUTATHERA® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION
References: 1. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp. 2. Hope TA, Abbott A, Colucci K, et al. NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177Lu DOTATATE. J Nucl Med. 2019;60:937-943.